** Brokerage BMO Capital Markets believes Danish drugmaker Novo Nordisk's NOVOb.CO obesity rival Eli Lilly LLY.N has made sizable advancements in its commercial and clinical portfolio, causing it to overtake Novo's early lead
** BMO cuts PT for Novo Nordisk NOVOb.CO to $64 from $105, downgrades stock rating to "market perform" from "outperform"
** BMO says Novo's "first mover advantage" with semaglutide, the active ingredient in its weight loss and diabetes drugs, has waned with Lilly's tirezepatide taking share rapidly
** BMO sees this trend accelerating with Lilly's experimental oral weight loss drug orforglipron and so-called "triple-G" weight-loss drug candidate retatrutide
** Brokerage also believes Novo will have a "softer Q1"
** Nineteen of 26 brokerages rate the stock "buy" or higher, 7 "hold" and 1 "sell" or lower; their median PT is 700 DKK ($106.66) - data compiled by LSEG
** Up to last close, stock down 32.5% YTD
($1 = 6.5628 Danish crowns)
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.